CRISPR Therapeutics AG (NASDAQ:CRSP) Director Acquires $313,950.00 in Stock

CRISPR Therapeutics AG (NASDAQ:CRSP) Director John Greene purchased 7,000 shares of the company’s stock in a transaction dated Wednesday, February 26th. The shares were acquired at an average price of $44.85 per share, for a total transaction of $313,950.00. Following the purchase, the director now owns 7,000 shares in the company, valued at $313,950. The trade was a ? increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

CRISPR Therapeutics Price Performance

Shares of NASDAQ CRSP traded up $0.30 during trading hours on Friday, reaching $43.92. The stock had a trading volume of 1,658,786 shares, compared to its average volume of 2,347,561. CRISPR Therapeutics AG has a twelve month low of $36.52 and a twelve month high of $89.88. The business’s fifty day moving average is $42.42 and its two-hundred day moving average is $45.97. The company has a market cap of $3.77 billion, a price-to-earnings ratio of -10.05 and a beta of 1.67.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) EPS for the quarter, topping analysts’ consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. Sell-side analysts forecast that CRISPR Therapeutics AG will post -5.16 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have commented on CRSP. StockNews.com raised shares of CRISPR Therapeutics to a “sell” rating in a research report on Thursday, February 13th. Royal Bank of Canada cut their price objective on CRISPR Therapeutics from $53.00 to $48.00 and set a “sector perform” rating on the stock in a research note on Wednesday, February 12th. HC Wainwright reaffirmed a “buy” rating and set a $65.00 target price on shares of CRISPR Therapeutics in a research report on Thursday, February 13th. Chardan Capital dropped their price target on shares of CRISPR Therapeutics from $94.00 to $84.00 and set a “buy” rating on the stock in a research report on Thursday, February 13th. Finally, Stifel Nicolaus decreased their price objective on shares of CRISPR Therapeutics from $53.00 to $49.00 and set a “hold” rating for the company in a report on Thursday, February 13th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $74.40.

Institutional Investors Weigh In On CRISPR Therapeutics

Several large investors have recently modified their holdings of CRSP. ARK Investment Management LLC lifted its position in shares of CRISPR Therapeutics by 19.7% during the 4th quarter. ARK Investment Management LLC now owns 8,973,064 shares of the company’s stock worth $353,180,000 after buying an additional 1,474,439 shares during the period. Capital International Investors lifted its holdings in shares of CRISPR Therapeutics by 10.3% during the fourth quarter. Capital International Investors now owns 8,743,523 shares of the company’s stock valued at $344,145,000 after acquiring an additional 816,789 shares during the period. T. Rowe Price Investment Management Inc. boosted its stake in shares of CRISPR Therapeutics by 39.2% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,811,708 shares of the company’s stock valued at $150,029,000 after purchasing an additional 1,074,238 shares in the last quarter. State Street Corp boosted its stake in shares of CRISPR Therapeutics by 25.0% in the 3rd quarter. State Street Corp now owns 2,992,988 shares of the company’s stock valued at $140,611,000 after purchasing an additional 599,304 shares in the last quarter. Finally, FMR LLC lifted its holdings in CRISPR Therapeutics by 1.0% during the 3rd quarter. FMR LLC now owns 2,376,166 shares of the company’s stock valued at $111,632,000 after purchasing an additional 23,075 shares during the last quarter. 69.20% of the stock is currently owned by institutional investors.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.